Your browser doesn't support javascript.
loading
[Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].
Luo, D; Luo, J; Liang, H; He, Z; Chen, H; Wen, Z; Wang, Q; Zhou, X; Liu, X; Xu, N.
Afiliación
  • Luo D; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Luo J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Liang H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • He Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Chen H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Wen Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Wang Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Zhou X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Liu X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • Xu N; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Nan Fang Yi Ke Da Xue Xue Bao ; 43(6): 1029-1034, 2023 Jun 20.
Article en Zh | MEDLINE | ID: mdl-37439177
OBJECTIVE: To evaluate the clinical efficacy and adverse reactions of peginterferon-α2b for treatment of chronic myeloproliferative neoplasms (MPN). METHODS: We retrospectively analyzed the data of 107 patients with MPN, including 95 with essential thrombocythemia (ET) and 12 with polycythemia vera (PV), who all received peginterferon-α2b treatment for at least 12 months. The clnical and follow-up data of the patients were analyzed to evaluate the efficacy and adverse reactions of the treatment. RESULTS: After receiving peginterferon- α2b treatment, both ET and PV patients achieved high hematological remission rates, and the total remission rates did not differ significantly between the two groups (86% vs 78%, P>0.05). In the overall patients, the spleen index decreased by 13.5% (95%CI: 8.5%-18.5%) after the treatment. The patients with hematological remission showed a significantly greater reduction of the total symptom score than those without hematological remission (P < 0.01). The median percentage of JAK2V617F allele load of PV patients decreased from 67.23% (49.6%-84.86%) at baseline to 19.7% (0.57%-74.6%) after the treatment, and that of JAK2V617F-positive ET patients decreased from 48.97% (0.45%-74.24%) at baseline to 22.1% (0.33%-65.42%) after the treatment. Mild adverse reactions (grade 1-2) were observed in both ET and PV groups without significant differences between them. The overall incidence of thrombotic events during the treatment was 2.8% in these patients, and no serious adverse reactions were observed. CONCLUSION: For patients with chronic myelodysplasia, peginterferon-α2b treatment can achieve a high peripheral blood cell remission rate and maintain a long-term stable state with good effect in relieving symptoms such as splenomegaly. Peginterferon- α2b treatment caused only mild adverse reactions, which can be tolerated by most of the patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferón alfa-2 / Neoplasias Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Nan Fang Yi Ke Da Xue Xue Bao Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferón alfa-2 / Neoplasias Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Nan Fang Yi Ke Da Xue Xue Bao Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China